Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Pathol. 2014 Aug;45(8):1630-8. doi: 10.1016/j.humpath.2014.03.014. Epub 2014 Apr 13.

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.

Author information

1
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905.
2
Abbott Molecular Diagnostics, Des Plaines, IL 60018.
3
Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905.
4
Department of Oncology, Mayo Clinic, Rochester, MN 55905.
5
Department of Health Science Research, Mayo Clinic, Rochester, MN 55905.
6
Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905.
7
Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259.
8
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: Kipp.Benjamin@mayo.edu.

Abstract

Patients with cholangiocarcinoma often present with locally advanced or metastatic disease. There is a need for effective therapeutic strategies for advanced stage cholangiocarcinoma. Recently, FGFR2 translocations have been identified as a potential target for tyrosine kinase inhibitor therapies. This study evaluated 152 cholangiocarcinomas and 4 intraductal papillary biliary neoplasms of the bile duct for presence of FGFR2 translocations by fluorescence in situ hybridization and characterized the clinicopathologic features of cases with FGFR2 translocations. Thirteen (10 women, 3 men; 8%) of 156 biliary tumors harbored FGFR2 translocations, including 12 intrahepatic cholangiocarcinomas (12/96; 13%) and 1 intraductal papillary neoplasm of the bile duct. Histologically, cholangiocarcinomas with FGFR2 translocations displayed prominent intraductal growth (62%) or anastomosing tubular glands with desmoplasia (38%). Immunohistochemically, the tumors with FGFR2 translocations frequently showed weak and patchy expression of CK19 (77%). Markers of the stem cell phenotype in cholangiocarcinoma, HepPar1 and CK20, were negative in all cases. The median cancer-specific survival for patients whose tumors harbored FGFR2 translocations was 123 months compared to 37 months for cases without FGFR2 translocations (P = .039). This study also assessed 100 cholangiocarcinomas for ERBB2 amplification and ROS1 translocations. Of the cases tested, 3% and 1% were positive for ERBB2 amplification and ROS1 translocation, respectively. These results confirm that FGFR2, ERRB2, and ROS1 alterations are potential therapeutic targets for intrahepatic cholangiocarcinoma.

KEYWORDS:

Bile; ERBB2; FGFR2; HER2; ROS1; Targeted therapy; Tyrosine kinase

PMID:
24837095
DOI:
10.1016/j.humpath.2014.03.014
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center